Completed
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers.
What is being tested
ChAdOx1 Zika
Biological
Who is being recruted
Zika Virus Infection+6
+ Vector Borne Diseases
+ Mosquito-Borne Diseases
From 18 to 50 Years
+34 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Study Start: October 2019
Summary
Principal SponsorUniversity of Oxford
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 21, 2019
Actual date on which the first participant was enrolled.Volunteers will be recruited and vaccinated at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford. There will be 3 study groups and a total of 24 volunteers will be enrolled. Groups 1-3 will receive ChAdOx1 Zika alone. Staggered enrolment will apply for the first three volunteers within each group.
Official TitleA Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers.
Principal SponsorUniversity of Oxford
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
24 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Zika Virus InfectionVector Borne DiseasesMosquito-Borne DiseasesArbovirus InfectionsInfectionsRNA Virus InfectionsVirus DiseasesFlavivirus InfectionsFlaviviridae Infections
Criteria
8 inclusion criteria required to participate
Healthy adults aged 18 to 50 years
Able and willing (in the Investigator's opinion) to comply with all study requirements
Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner or access to this medical history electronically (or providing their medical case summaries)
Women of child-bearing potential agree to practice continuous effective contraception (see below) during the study and test negative for pregnancy on the day(s) of screening and vaccination.
Show More Criteria
26 exclusion criteria prevent from participating
Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine, Zika virus vaccine, Dengue virus vaccine).
Prior receipt of any vaccines administered ≤30 days before enrolment and/or planned receipt of a vaccine ≤30 days after enrolment EXCEPT for protein, RNA (or other non-adenovirus based) COVID-19 vaccinations which may be given within 14 days of the trial vaccine.
Receipt of recombinant simian adenoviral vaccine prior to enrolment.
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalVolunteers will receive standalone dose of ChAdOx1 Zika 5 x 10\^9 vp vaccination intramuscularly.
Group II
ExperimentalVolunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10\^10 vp vaccination intramuscularly.
Group III
ExperimentalVolunteers will receive standalone dose of ChAdOx1 Zika 5 x 10\^10 vp vaccination intramuscularly.
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CCVTM, University of Oxford, Churchill Hospital
Oxford, United KingdomOpen CCVTM, University of Oxford, Churchill Hospital in Google MapsCompletedOne Study Center